SCHEDULE: Armistice Capital Discloses 6.73% Stake in Orthofix Medical

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 2,700,000 shares, representing 6.73% of Orthofix Medical Inc.'s common stock, as of March 31, 2026.

Summary

• Armistice Capital, LLC, an investment manager, and Steven Boyd, its managing member, have jointly filed a Schedule 13G, indicating their beneficial ownership of Orthofix Medical Inc. (ORFX) common stock.
• The filing reports a total of 2,700,000 shares owned, which constitutes 6.73% of the class of securities.
• This ownership stake is held through Armistice Capital Master Fund Ltd., which is managed by Armistice Capital, LLC.
• Steven Boyd, as the managing member of Armistice Capital, LLC, is also deemed to beneficially own these shares.
• The filing specifies that Armistice Capital, LLC has shared voting power and shared dispositive power over these shares, while sole voting and dispositive power is reported as zero.
• The Master Fund, the direct holder, disclaims beneficial ownership due to the investment management agreement with Armistice Capital.
• The filing was made on May 15, 2026, with the event date requiring the filing being March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily a disclosure of ownership without immediate implications for the company's operational or financial performance, though it signals increased investor attention.

Positives

• Armistice Capital, LLC and Steven Boyd have disclosed a significant ownership stake of 6.73% in Orthofix Medical Inc., indicating investor confidence or strategic interest.
• The reporting persons have shared voting and dispositive power, suggesting active management and potential influence over the shares held.

Negatives

• The Master Fund, the direct holder of the shares, explicitly disclaims beneficial ownership, which could imply a complex ownership structure or limitations on direct control.
• The filing does not provide details on the acquisition cost or strategy behind this stake, leaving the investment rationale open to interpretation.

Risks

• Potential for increased scrutiny from management or other shareholders regarding Armistice Capital's intentions with its 6.73% stake.
• The disclaimer of beneficial ownership by the Master Fund could indicate potential future changes in control or voting arrangements.
• As a Schedule 13G filing, it suggests passive investment, but any shift towards active engagement could introduce governance risks or activist investor concerns.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Orthofix Medical Inc.'s future performance.

Industry Context

StockSavvy.ai notes that significant stake disclosures via Schedule 13G filings often signal a shift in institutional interest or potential activist involvement within the medical device sector, an industry characterized by innovation and consolidation.

Stakeholder Impact

• Shareholders: May view the increased institutional interest positively, potentially leading to greater scrutiny of management or strategic initiatives.
• Management: May need to engage with Armistice Capital, LLC regarding their investment strategy and intentions.
• Creditors: Unlikely to be directly impacted by this ownership disclosure.

Next Steps

• Monitor future filings from Armistice Capital, LLC and Steven Boyd for any changes in ownership or potential strategic actions.
• Observe Orthofix Medical Inc.'s response, if any, to this disclosure.

Key Dates

Keywords

Orthofix Medical, Schedule 13G, Armistice Capital, Steven Boyd, Beneficial Ownership, SEC Filing, Common Stock, Investment Management, Shareholder, ORFX